RecruitingPhase 2psilocybin

Psilocybin Therapy for Depression in Parkinson's Disease

Sponsored by Joshua Woolley, MD, PhD

NCT ID
NCT06455293
Target Enrollment
60 participants
Start Date
2024-08-19
Est. Completion
2028-06

About This Study

The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.

Conditions Studied

Parkinson DiseaseDepression

Interventions

  • Psilocybin

Eligibility

Age:40 Years - 80 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* Age 40 to 80
* Comfortable speaking and writing in English
* Have neurologist-diagnosed idiopathic Parkinson's disease (PD), Hoehn and Yahr stages 1 to 3 during an "on" phase (time when medication/DBS for parkinsonian motor feature, including bradykinesia and rigidity is in effect)
* Currently experiencing depressive symptoms
* Able to attend all in-person visits at UCSF as well as virtual visits
* Have a primary care provider, neurologist, or psychiatrist who is actively managing or coordinating

Exclusion Criteria:

* Psychotic symptoms involving loss of insight
* Significant cognitive impairment
* Regular use of medications that may have problematic interactions with psilocybin
* A health condition that makes this study unsafe or unfeasible, determined by study physicians

Study Locations (1)

University of California, San Francisco
San Francisco, California, United States

Interested in this trial?

Contact the study team to learn more about eligibility and enrollment.

Brigette Sosa
CONTACT
(415) 935-3489pdp2@ucsf.edu
Ellen Bradley, MD
CONTACT
ellen.bradley@ucsf.edu
View on ClinicalTrials.gov
Data Source
ClinicalTrials.gov

Last updated from source

Psilocybin Therapy for Depression in Parkinson's Disease | Huxley